Titlebook: Cancer Gene Therapy; Past Achievements an Nagy A. Habib Book 2002 The Editor(s) (if applicable) and The Author(s), under exclusive license

Denial

書目名稱Cancer Gene Therapy影響因子(影響力)




書目名稱Cancer Gene Therapy影響因子(影響力)學(xué)科排名




書目名稱Cancer Gene Therapy網(wǎng)絡(luò)公開度




書目名稱Cancer Gene Therapy網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Cancer Gene Therapy被引頻次




書目名稱Cancer Gene Therapy被引頻次學(xué)科排名




書目名稱Cancer Gene Therapy年度引用




書目名稱Cancer Gene Therapy年度引用學(xué)科排名




書目名稱Cancer Gene Therapy讀者反饋




書目名稱Cancer Gene Therapy讀者反饋學(xué)科排名

flammable

Polyoma and Papilloma Virus Vectors For Cancer Gene Therapyattempted, or where viruses (for example, papillo-maviruses, Epstein Barr virus, or herpesvirus-8) have been implicated in tumour formation, an approach aimed at inhibiting expression of identified oncogenic functions could be explored. These methods, coupled with stimulation of T cell killing by el

Oratory

Killer/DR5, A Novel DNA-Damage Inducible Death Receptor Gene, Links the p53-Tumor Suppressor to Casp for cancer treatment. TRAIL appears to be a cancer-specific cytotoxic agent and thus offers promise as a novel therapy for cancer either through replacement of the cytokine or potentially via gene replacement. Preliminary studies suggest the potential to combine TRAIL with classical cytotoxic chemo

清澈

明確

Book 2002em of transferring the therapeutic gene into the cancer cell has been partly addressed with major developments in the field of naked plasmid DNA, adenovirus, retrovirus and adeno-associated viruses. However, further improvements are yet to be made to achieve significant gene transfer. Gene expressio

FUSC

Erik Cuevas,Fernando Fausto,Adrián Gonzálezare rapidly growing with new journals and meetings solely devoted to this subject increasing annually. Within the next 5 years, we should have mean-ingful clinical data on targetable vectors to reassess our progress.

FUSC

J. Delgado,E. A. Lacomba,E. Pérez-Chavelaattempted, or where viruses (for example, papillo-maviruses, Epstein Barr virus, or herpesvirus-8) have been implicated in tumour formation, an approach aimed at inhibiting expression of identified oncogenic functions could be explored. These methods, coupled with stimulation of T cell killing by el

Flagging

https://doi.org/10.1007/978-4-431-68093-2 for cancer treatment. TRAIL appears to be a cancer-specific cytotoxic agent and thus offers promise as a novel therapy for cancer either through replacement of the cytokine or potentially via gene replacement. Preliminary studies suggest the potential to combine TRAIL with classical cytotoxic chemo

CANT

Myofibrils

The Use Of Skeletal Muscle To Express Genes For The Treatment Of Cancer